CBX2 Identified As Driver of Anoikis Escape and Dissemination in High Grade Serous Ovarian Cancer

Overview

Journal Oncogenesis

Date 2018 Nov 28

PMID 30478317

Citations 46

Authors

Lindsay J Wheeler

Zachary L Watson

Lubna Qamar

Tomomi M Yamamoto

Miriam D Post

Amber A Berning

Monique A Spillman

Kian Behbakht

Benjamin G Bitler

Affiliations

Soon will be listed here.

Abstract

High grade serous ovarian carcinoma (HGSOC) is often diagnosed at an advanced stage. Chromobox 2 (CBX2), a polycomb repressor complex subunit, plays an oncogenic role in other cancers, but little is known about its role in HGSOC. We hypothesize that CBX2 upregulation promotes HGSOC via induction of a stem-like transcriptional profile and inhibition of anoikis. Examination of Gene Expression Omnibus (GEO) datasets and The Cancer Genome Atlas (TCGA) established that increased CBX2 expression conveyed chemoresistance and worse disease-free and overall survival. In primary HGSOC tumors, we observed CBX2 expression was significantly elevated compared to benign counterparts. In HGSOC cell lines, forced suspension promoted CBX2 expression. Subsequently, CBX2 knockdown inhibited anchorage-independent proliferation and potentiated anoikis-dependent apoptosis. Furthermore, CBX2 knockdown re-sensitized cells to platinum-based chemotherapy. Forced suspension promoted increased ALDH activity and ALDH3A1 expression and CBX2 knockdown led to a decrease in both ALDH activity and ALDH3A1 expression. Investigation of CBX2 expression on a HGSOC tissue microarray revealed CBX2 expression was apparent in both primary and metastatic tissues. CBX2 is an important regulator of stem-ness, anoikis escape, HGSOC dissemination, and chemoresistance and potentially serves as a novel therapeutic target.

Citing Articles

Epigenetic regulatory protein chromobox family regulates multiple signalling pathways and mechanisms in cancer.

Su W, Wang W, Zhang G, Yang L Clin Epigenetics. 2025; 17(1):48.

PMID: 40083014 PMC: 11907984. DOI: 10.1186/s13148-025-01852-w.

Metabolic reprogramming and signaling adaptations in anoikis resistance: mechanisms and therapeutic targets.

He C, He J Mol Cell Biochem. 2025; .

PMID: 39821582 DOI: 10.1007/s11010-024-05199-3.

CBX2 promotes cervical cancer cell proliferation and resistance to DNA-damaging treatment via maintaining cancer stemness.

Li W, Shi R, Gao Y, Wang X, Shen T, Liu X J Biol Chem. 2025; 301(2):108170.

PMID: 39793896 PMC: 11835617. DOI: 10.1016/j.jbc.2025.108170.

Anoikis in cell fate, physiopathology, and therapeutic interventions.

Mei J, Jiang X, Tian H, Rong D, Song J, Wang L MedComm (2020). 2024; 5(10):e718.

PMID: 39286778 PMC: 11401975. DOI: 10.1002/mco2.718.

The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma.

Van Kleunen L, Ahmadian M, Post M, Wolsky R, Rickert C, Jordan K Cancer Immunol Res. 2024; 12(11):1492-1507.

PMID: 39115368 PMC: 11534564. DOI: 10.1158/2326-6066.CIR-23-1109.

References

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E . Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2017; 61(2):462-481. PMC: 5788414. DOI: 10.1021/acs.jmedchem.6b01816. View

Buchheit C, Weigel K, Schafer Z . Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014; 14(9):632-41. DOI: 10.1038/nrc3789. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Li H, Cai Q, Godwin A, Zhang R . Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res. 2010; 8(12):1610-8. PMC: 3059727. DOI: 10.1158/1541-7786.MCR-10-0398. View

Amatangelo M, Garipov A, Li H, Conejo-Garcia J, Speicher D, Zhang R . Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle. 2013; 12(13):2113-9. PMC: 3737313. DOI: 10.4161/cc.25163. View

Clark R, Krishnan V, Schoof M, Rodriguez I, Theriault B, Chekmareva M . Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models. Am J Pathol. 2013; 183(2):576-91. PMC: 3730760. DOI: 10.1016/j.ajpath.2013.04.023. View

Li H, Bitler B, Vathipadiekal V, Maradeo M, Slifker M, Creasy C . ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila). 2011; 5(3):484-91. PMC: 3294119. DOI: 10.1158/1940-6207.CAPR-11-0414. View

Zhang S, Balch C, Chan M, Lai H, Matei D, Schilder J . Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68(11):4311-20. PMC: 2553722. DOI: 10.1158/0008-5472.CAN-08-0364. View

10.

Zhou Y, Zhu Y, Fan X, Zhang C, Wang Y, Zhang L . NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells. Oncotarget. 2017; 8(20):33110-33121. PMC: 5464854. DOI: 10.18632/oncotarget.16145. View

11.

Richly H, Aloia L, Di Croce L . Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis. 2011; 2:e204. PMC: 3186902. DOI: 10.1038/cddis.2011.84. View

12.

Intidhar Labidi-Galy S, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M . High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017; 8(1):1093. PMC: 5653668. DOI: 10.1038/s41467-017-00962-1. View

13.

Yoshida H, Cheng W, Hung J, Montell D, Geisbrecht E, Rosen D . Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci U S A. 2004; 101(21):8144-9. PMC: 419571. DOI: 10.1073/pnas.0400400101. View

14.

Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry M . Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2013; 123(5):697-705. DOI: 10.1182/blood-2013-01-478420. View

15.

Latifi A, Luwor R, Bilandzic M, Nazaretian S, Stenvers K, Pyman J . Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 2012; 7(10):e46858. PMC: 3466197. DOI: 10.1371/journal.pone.0046858. View

16.

Vervoort S, van Boxtel R, Coffer P . The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe?. Oncogene. 2012; 32(29):3397-409. DOI: 10.1038/onc.2012.506. View

17.

Cronin K, Ries L, Edwards B . The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer. 2014; 120 Suppl 23:3755-7. DOI: 10.1002/cncr.29049. View

18.

Clermont P, Crea F, Chiang Y, Lin D, Zhang A, Wang J . Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin Epigenetics. 2016; 8:16. PMC: 4751702. DOI: 10.1186/s13148-016-0182-9. View

19.

Kim S, Kim B, Song Y . Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016; 107(9):1173-8. PMC: 5021036. DOI: 10.1111/cas.12987. View

20.

Mootha V, Lindgren C, Eriksson K, Subramanian A, Sihag S, Lehar J . PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34(3):267-73. DOI: 10.1038/ng1180. View